FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890213863> ?p ?o ?g. }

• W2890213863 abstract "e14080 Background: Venous thromboembolism (VTE) is a common and often serious complication for patients with malignancy. Even though low molecular weight heparin (LMWH) is recommended as first line therapy for initial and long term anticoagulation, patient choice may demand oral anticoagulants. This retrospective review illustrates the repeated observation of recurrent thromboembolic disease in patients taking the new class of oral anticoagulant, DOAC. Methods: The pharmacy database at our institution was searched to identify oncology patients who had received a prescription for a DOAC (rivaroxaban or apixiban). Sixtyfive patients were identified and case records were then examined for evidence of venous thromboembolism. Results: Five seperate episodes of recurrent venous thromboembolism were identified in four patients in our cohort., one patient having two seperate episodes of pulmonary embolus. All were on recommended therapeutic doses of DOAC at the time of thromboembolic event. Two patients experienced proven pulmonary embolus on CT pulmonary angiography (1 twice), one lower limb deep vein thrombosis and one upper limb deep vein thrombosis. Conclusions: This retrosepctive review reinforces the clinical guidelines stated by the Cochrane review and ASCO that LMWH should always be first line for the initial and continuation treatment of a VTE. The guidelines did not focus on the suboptimal anticoagulation aspect of the newer oral anticoagulants but more on the safety issues. Research has been mainly focused on comparing LMWH with unfractionated heparin (UFH) or oral warfarin. Comparisons between DOAC versus Warfarin as an oral form of therapy have also been made. In the available published literature, there is a paucity of research comparing DOACs to LMWH. We have identified four patients out of sixtyfive treated with therapeutic doses of DOAC who developed subsequent thromboembolism. This is additional supportive evidence that newer oral anticoagulant agents may not be efficacious in malignancy driven VTE and that LMWH should remain the standard of care. Patients specifically requesting DOAC for cancer associated VTE should be made aware of this data." @default.
• W2890213863 created "2018-09-27" @default.
• W2890213863 creator A5021084770 @default.
• W2890213863 creator A5052709676 @default.
• W2890213863 date "2017-05-20" @default.
• W2890213863 modified "2023-09-27" @default.
• W2890213863 title "Cancer associated thrombosis in patients taking direct oral anticoagulants (DOACs): Retrospective review of a single institutional series." @default.
• W2890213863 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14080" @default.
• W2890213863 hasPublicationYear "2017" @default.
• W2890213863 type Work @default.
• W2890213863 sameAs 2890213863 @default.
• W2890213863 citedByCount "0" @default.
• W2890213863 crossrefType "journal-article" @default.
• W2890213863 hasAuthorship W2890213863A5021084770 @default.
• W2890213863 hasAuthorship W2890213863A5052709676 @default.
• W2890213863 hasConcept C121608353 @default.
• W2890213863 hasConcept C126322002 @default.
• W2890213863 hasConcept C141071460 @default.
• W2890213863 hasConcept C167135981 @default.
• W2890213863 hasConcept C177713679 @default.
• W2890213863 hasConcept C2780073493 @default.
• W2890213863 hasConcept C2780868729 @default.
• W2890213863 hasConcept C71924100 @default.
• W2890213863 hasConceptScore W2890213863C121608353 @default.
• W2890213863 hasConceptScore W2890213863C126322002 @default.
• W2890213863 hasConceptScore W2890213863C141071460 @default.
• W2890213863 hasConceptScore W2890213863C167135981 @default.
• W2890213863 hasConceptScore W2890213863C177713679 @default.
• W2890213863 hasConceptScore W2890213863C2780073493 @default.
• W2890213863 hasConceptScore W2890213863C2780868729 @default.
• W2890213863 hasConceptScore W2890213863C71924100 @default.
• W2890213863 hasLocation W28902138631 @default.
• W2890213863 hasOpenAccess W2890213863 @default.
• W2890213863 hasPrimaryLocation W28902138631 @default.
• W2890213863 hasRelatedWork W1770681270 @default.
• W2890213863 hasRelatedWork W2288464804 @default.
• W2890213863 hasRelatedWork W2470515176 @default.
• W2890213863 hasRelatedWork W2614375319 @default.
• W2890213863 hasRelatedWork W2749004989 @default.
• W2890213863 hasRelatedWork W2799780795 @default.
• W2890213863 hasRelatedWork W2886275742 @default.
• W2890213863 hasRelatedWork W2900864013 @default.
• W2890213863 hasRelatedWork W2916375296 @default.
• W2890213863 hasRelatedWork W2923575318 @default.
• W2890213863 hasRelatedWork W2932112037 @default.
• W2890213863 hasRelatedWork W2945301729 @default.
• W2890213863 hasRelatedWork W2951978162 @default.
• W2890213863 hasRelatedWork W2955817013 @default.
• W2890213863 hasRelatedWork W3021702911 @default.
• W2890213863 hasRelatedWork W3041638651 @default.
• W2890213863 hasRelatedWork W3045755791 @default.
• W2890213863 hasRelatedWork W3158848750 @default.
• W2890213863 hasRelatedWork W3195559889 @default.
• W2890213863 hasRelatedWork W3202230529 @default.
• W2890213863 isParatext "false" @default.
• W2890213863 isRetracted "false" @default.
• W2890213863 magId "2890213863" @default.
• W2890213863 workType "article" @default.